Association  ||| S:0 E:12 ||| NNP
of  ||| S:12 E:15 ||| IN
serum  ||| S:15 E:21 ||| JJ
folic  ||| S:21 E:27 ||| JJ
acid  ||| S:27 E:32 ||| NN
and  ||| S:32 E:36 ||| CC
homocysteine  ||| S:36 E:49 ||| JJ
levels  ||| S:49 E:56 ||| NNS
and  ||| S:56 E:60 ||| CC
5 ||| S:60 E:61 ||| CD
,  ||| S:61 E:63 ||| ,
10-methylenetetrahydrofolate  ||| S:63 E:92 ||| CD
reductase  ||| S:92 E:102 ||| JJ
gene  ||| S:102 E:107 ||| NN
polymorphism  ||| S:107 E:120 ||| NN
with  ||| S:120 E:125 ||| IN
schizophrenia  ||| S:125 E:139 ||| NN
To  ||| S:139 E:142 ||| TO
explore  ||| S:142 E:150 ||| VB
the  ||| S:150 E:154 ||| DT
association  ||| S:154 E:166 ||| NN
between  ||| S:166 E:174 ||| IN
serum  ||| S:174 E:180 ||| JJ
concentrations  ||| S:180 E:195 ||| NNS
of  ||| S:195 E:198 ||| IN
folic  ||| S:198 E:204 ||| JJ
acid  ||| S:204 E:209 ||| NN
and  ||| S:209 E:213 ||| CC
homocysteine  ||| S:213 E:226 ||| NNS
( ||| S:226 E:227 ||| -LRB-
HCY ||| S:227 E:230 ||| NNP
) ||| S:230 E:231 ||| -RRB-
,  ||| S:231 E:233 ||| ,
5 ||| S:233 E:234 ||| CD
,  ||| S:234 E:236 ||| ,
10-methylenetetrahydrofolate  ||| S:236 E:265 ||| CD
reductase  ||| S:265 E:275 ||| NNS
( ||| S:275 E:276 ||| -LRB-
MTHFR ||| S:276 E:281 ||| NNP
)  ||| S:281 E:283 ||| -RRB-
C667T  ||| S:283 E:289 ||| CD
polymorphism  ||| S:289 E:302 ||| NNS
and  ||| S:302 E:306 ||| CC
schizophrenia ||| S:306 E:319 ||| NN
.  ||| S:319 E:321 ||| .
A  ||| S:321 E:323 ||| DT
total  ||| S:323 E:329 ||| NN
of  ||| S:329 E:332 ||| IN
130  ||| S:332 E:336 ||| CD
schizophrenics  ||| S:336 E:351 ||| NNS
( ||| S:351 E:352 ||| -LRB-
schizophrenia  ||| S:352 E:366 ||| JJ
group ||| S:366 E:371 ||| NN
)  ||| S:371 E:373 ||| -RRB-
from  ||| S:373 E:378 ||| IN
our  ||| S:378 E:382 ||| PRP$
hospital  ||| S:382 E:391 ||| NN
and  ||| S:391 E:395 ||| CC
80  ||| S:395 E:398 ||| CD
healthy  ||| S:398 E:406 ||| JJ
individuals  ||| S:406 E:418 ||| NNS
( ||| S:418 E:419 ||| -LRB-
control  ||| S:419 E:427 ||| NN
group ||| S:427 E:432 ||| NN
)  ||| S:432 E:434 ||| -RRB-
were  ||| S:434 E:439 ||| VBD
enrolled ||| S:439 E:447 ||| VBN
.  ||| S:447 E:449 ||| .
The  ||| S:449 E:453 ||| DT
serum  ||| S:453 E:459 ||| JJ
concentration  ||| S:459 E:473 ||| NN
of  ||| S:473 E:476 ||| IN
homocysteine  ||| S:476 E:489 ||| NN
was  ||| S:489 E:493 ||| VBD
measured  ||| S:493 E:502 ||| VBN
by  ||| S:502 E:505 ||| IN
the  ||| S:505 E:509 ||| DT
electrochemical  ||| S:509 E:525 ||| JJ
luminescence  ||| S:525 E:538 ||| JJ
method ||| S:538 E:544 ||| NN
,  ||| S:544 E:546 ||| ,
the  ||| S:546 E:550 ||| DT
concentration  ||| S:550 E:564 ||| NN
of  ||| S:564 E:567 ||| IN
serum  ||| S:567 E:573 ||| JJ
folic  ||| S:573 E:579 ||| JJ
acid  ||| S:579 E:584 ||| NN
by  ||| S:584 E:587 ||| IN
enzymatic  ||| S:587 E:597 ||| JJ
cycling  ||| S:597 E:605 ||| NN
assay  ||| S:605 E:611 ||| NNS
and  ||| S:611 E:615 ||| CC
MTHFR  ||| S:615 E:621 ||| NNP
C667T  ||| S:621 E:627 ||| NNP
genotype  ||| S:627 E:636 ||| NN
by  ||| S:636 E:639 ||| IN
PCR-DNA  ||| S:639 E:647 ||| JJ
microarray ||| S:647 E:657 ||| NN
.  ||| S:657 E:659 ||| .
And  ||| S:659 E:663 ||| CC
positive  ||| S:663 E:672 ||| JJ
and  ||| S:672 E:676 ||| CC
negative  ||| S:676 E:685 ||| JJ
syndrome  ||| S:685 E:694 ||| NN
scale  ||| S:694 E:700 ||| NN
( ||| S:700 E:701 ||| -LRB-
PANSS ||| S:701 E:706 ||| NNP
)  ||| S:706 E:708 ||| -RRB-
was  ||| S:708 E:712 ||| VBD
used  ||| S:712 E:717 ||| VBN
to  ||| S:717 E:720 ||| TO
evaluate  ||| S:720 E:729 ||| VB
the  ||| S:729 E:733 ||| DT
mental  ||| S:733 E:740 ||| JJ
symptoms.  ||| S:740 E:750 ||| NNP
( ||| S:750 E:751 ||| -LRB-
1 ||| S:751 E:752 ||| LS
)  ||| S:752 E:754 ||| -RRB-
Serum  ||| S:754 E:760 ||| NNP
HCY  ||| S:760 E:764 ||| NNP
level  ||| S:764 E:770 ||| NN
in  ||| S:770 E:773 ||| IN
schizophrenia  ||| S:773 E:787 ||| JJ
group  ||| S:787 E:793 ||| NN
was  ||| S:793 E:797 ||| VBD
higher  ||| S:797 E:804 ||| JJR
than  ||| S:804 E:809 ||| IN
that  ||| S:809 E:814 ||| DT
in  ||| S:814 E:817 ||| IN
control  ||| S:817 E:825 ||| NN
group  ||| S:825 E:831 ||| NN
[ ||| S:831 E:832 ||| -LRB-
( ||| S:832 E:833 ||| -LRB-
20  ||| S:833 E:836 ||| CD
±  ||| S:836 E:838 ||| CD
10 ||| S:838 E:840 ||| CD
)  ||| S:840 E:842 ||| -RRB-
vs  ||| S:842 E:845 ||| NNS
( ||| S:845 E:846 ||| -LRB-
11  ||| S:846 E:849 ||| CD
±  ||| S:849 E:851 ||| CD
3 ||| S:851 E:852 ||| CD
)  ||| S:852 E:854 ||| -RRB-
µmol ||| S:854 E:858 ||| FW
/ ||| S:858 E:859 ||| FW
L ||| S:859 E:860 ||| NNP
;  ||| S:860 E:862 ||| :
P  ||| S:862 E:864 ||| NNP
< ||| S:864 E:866 ||| SYM
0.001 ||| S:866 E:871 ||| NNP
]  ||| S:871 E:873 ||| -RRB-
while  ||| S:873 E:879 ||| IN
serum  ||| S:879 E:885 ||| JJ
folate  ||| S:885 E:892 ||| JJ
level  ||| S:892 E:898 ||| NN
in  ||| S:898 E:901 ||| IN
schizophrenia  ||| S:901 E:915 ||| JJ
group  ||| S:915 E:921 ||| NN
was  ||| S:921 E:925 ||| VBD
lower  ||| S:925 E:931 ||| JJR
than  ||| S:931 E:936 ||| IN
that  ||| S:936 E:941 ||| DT
in  ||| S:941 E:944 ||| IN
control  ||| S:944 E:952 ||| NN
group  ||| S:952 E:958 ||| NN
[ ||| S:958 E:959 ||| -LRB-
( ||| S:959 E:960 ||| -LRB-
6  ||| S:960 E:962 ||| CD
±  ||| S:962 E:964 ||| CD
4 ||| S:964 E:965 ||| CD
)  ||| S:965 E:967 ||| -RRB-
vs  ||| S:967 E:970 ||| NNS
( ||| S:970 E:971 ||| -LRB-
9  ||| S:971 E:973 ||| CD
±  ||| S:973 E:975 ||| CD
3 ||| S:975 E:976 ||| CD
)  ||| S:976 E:978 ||| -RRB-
ng ||| S:978 E:980 ||| FW
/ ||| S:980 E:981 ||| FW
ml ||| S:981 E:983 ||| FW
;  ||| S:983 E:985 ||| :
P  ||| S:985 E:987 ||| NNP
< ||| S:987 E:989 ||| SYM
0.001 ||| S:989 E:994 ||| NNP
] ||| S:994 E:995 ||| -RRB-
;  ||| S:995 E:997 ||| :
( ||| S:997 E:998 ||| -LRB-
2 ||| S:998 E:999 ||| LS
)  ||| S:999 E:1001 ||| -RRB-
the  ||| S:1001 E:1005 ||| DT
frequencies  ||| S:1005 E:1017 ||| NN
of  ||| S:1017 E:1020 ||| IN
CC ||| S:1020 E:1022 ||| NNP
,  ||| S:1022 E:1024 ||| ,
CT  ||| S:1024 E:1027 ||| NNP
and  ||| S:1027 E:1031 ||| CC
TT  ||| S:1031 E:1034 ||| NNP
in  ||| S:1034 E:1037 ||| IN
MTHFR  ||| S:1037 E:1043 ||| NNP
C677T  ||| S:1043 E:1049 ||| NNP
alleles  ||| S:1049 E:1057 ||| NN
were  ||| S:1057 E:1062 ||| VBD
13.1 ||| S:1062 E:1066 ||| CD
% ||| S:1066 E:1067 ||| NN
,  ||| S:1067 E:1069 ||| ,
50.0 ||| S:1069 E:1073 ||| CD
%  ||| S:1073 E:1075 ||| NN
and  ||| S:1075 E:1079 ||| CC
36.9 ||| S:1079 E:1083 ||| CD
%  ||| S:1083 E:1085 ||| NN
in  ||| S:1085 E:1088 ||| IN
schizophrenia  ||| S:1088 E:1102 ||| JJ
group  ||| S:1102 E:1108 ||| NN
versus  ||| S:1108 E:1115 ||| IN
30.0 ||| S:1115 E:1119 ||| CD
% ||| S:1119 E:1120 ||| NN
,  ||| S:1120 E:1122 ||| ,
47.5 ||| S:1122 E:1126 ||| CD
%  ||| S:1126 E:1128 ||| NN
and  ||| S:1128 E:1132 ||| CC
22.5 ||| S:1132 E:1136 ||| CD
%  ||| S:1136 E:1138 ||| NN
in  ||| S:1138 E:1141 ||| IN
control  ||| S:1141 E:1149 ||| NN
group  ||| S:1149 E:1155 ||| NN
respectively ||| S:1155 E:1167 ||| RB
.  ||| S:1167 E:1169 ||| .
Statistical  ||| S:1169 E:1181 ||| JJ
significant  ||| S:1181 E:1193 ||| JJ
inter-group  ||| S:1193 E:1205 ||| JJ
difference  ||| S:1205 E:1216 ||| NN
existed  ||| S:1216 E:1224 ||| VBD
in  ||| S:1224 E:1227 ||| IN
the  ||| S:1227 E:1231 ||| DT
frequencies  ||| S:1231 E:1243 ||| NN
of  ||| S:1243 E:1246 ||| IN
genotypes  ||| S:1246 E:1256 ||| NNS
( ||| S:1256 E:1257 ||| -LRB-
χ²  ||| S:1257 E:1260 ||| CD
=  ||| S:1260 E:1262 ||| SYM
36.806 ||| S:1262 E:1268 ||| CD
,  ||| S:1268 E:1270 ||| ,
P  ||| S:1270 E:1272 ||| NN
< ||| S:1272 E:1274 ||| SYM
0.05 ||| S:1274 E:1278 ||| CD
)  ||| S:1278 E:1280 ||| -RRB-
.  ||| S:1280 E:1282 ||| .
The  ||| S:1282 E:1286 ||| DT
frequencies  ||| S:1286 E:1298 ||| NN
of  ||| S:1298 E:1301 ||| IN
T  ||| S:1301 E:1303 ||| NN
and  ||| S:1303 E:1307 ||| CC
C  ||| S:1307 E:1309 ||| NNP
alleles  ||| S:1309 E:1317 ||| NN
were  ||| S:1317 E:1322 ||| VBD
61.9 ||| S:1322 E:1326 ||| CD
% ||| S:1326 E:1327 ||| NN
,  ||| S:1327 E:1329 ||| ,
38.1 ||| S:1329 E:1333 ||| CD
%  ||| S:1333 E:1335 ||| NN
in  ||| S:1335 E:1338 ||| IN
schizophrenia  ||| S:1338 E:1352 ||| JJ
group  ||| S:1352 E:1358 ||| NN
versus  ||| S:1358 E:1365 ||| IN
46.25 ||| S:1365 E:1370 ||| CD
% ||| S:1370 E:1371 ||| NN
,  ||| S:1371 E:1373 ||| ,
53.75 ||| S:1373 E:1378 ||| CD
%  ||| S:1378 E:1380 ||| NN
in  ||| S:1380 E:1383 ||| IN
control  ||| S:1383 E:1391 ||| NN
group  ||| S:1391 E:1397 ||| NN
respectively ||| S:1397 E:1409 ||| RB
.  ||| S:1409 E:1411 ||| .
Statistical  ||| S:1411 E:1423 ||| JJ
significant  ||| S:1423 E:1435 ||| JJ
inter-group  ||| S:1435 E:1447 ||| JJ
difference  ||| S:1447 E:1458 ||| NN
existed  ||| S:1458 E:1466 ||| VBD
in  ||| S:1466 E:1469 ||| IN
the  ||| S:1469 E:1473 ||| DT
frequency  ||| S:1473 E:1483 ||| NN
of  ||| S:1483 E:1486 ||| IN
T  ||| S:1486 E:1488 ||| NN
allele  ||| S:1488 E:1495 ||| NNS
( ||| S:1495 E:1496 ||| -LRB-
χ²  ||| S:1496 E:1499 ||| CD
=  ||| S:1499 E:1501 ||| SYM
9.872 ||| S:1501 E:1506 ||| CD
,  ||| S:1506 E:1508 ||| ,
P  ||| S:1508 E:1510 ||| NN
< ||| S:1510 E:1512 ||| SYM
0.05 ||| S:1512 E:1516 ||| CD
) ||| S:1516 E:1517 ||| -RRB-
.  ||| S:1517 E:1519 ||| .
The  ||| S:1519 E:1523 ||| DT
frequency  ||| S:1523 E:1533 ||| NN
of  ||| S:1533 E:1536 ||| IN
TT  ||| S:1536 E:1539 ||| NNP
genotype  ||| S:1539 E:1548 ||| NN
in  ||| S:1548 E:1551 ||| IN
schizophrenia  ||| S:1551 E:1565 ||| JJ
group  ||| S:1565 E:1571 ||| NN
was  ||| S:1571 E:1575 ||| VBD
61.9 ||| S:1575 E:1579 ||| CD
%  ||| S:1579 E:1581 ||| NN
versus  ||| S:1581 E:1588 ||| IN
22.5 ||| S:1588 E:1592 ||| CD
%  ||| S:1592 E:1594 ||| NN
in  ||| S:1594 E:1597 ||| IN
control  ||| S:1597 E:1605 ||| NN
group ||| S:1605 E:1610 ||| NN
.  ||| S:1610 E:1612 ||| .
Statistically  ||| S:1612 E:1626 ||| RB
significant  ||| S:1626 E:1638 ||| JJ
inter-group  ||| S:1638 E:1650 ||| JJ
difference  ||| S:1650 E:1661 ||| NN
existed  ||| S:1661 E:1669 ||| VBD
in  ||| S:1669 E:1672 ||| IN
the  ||| S:1672 E:1676 ||| DT
frequency  ||| S:1676 E:1686 ||| NN
of  ||| S:1686 E:1689 ||| IN
TT  ||| S:1689 E:1692 ||| NNP
homozygous  ||| S:1692 E:1703 ||| FW
mutation  ||| S:1703 E:1712 ||| FW
( ||| S:1712 E:1713 ||| -LRB-
χ²  ||| S:1713 E:1716 ||| CD
=  ||| S:1716 E:1718 ||| SYM
4.780 ||| S:1718 E:1723 ||| CD
,  ||| S:1723 E:1725 ||| ,
P  ||| S:1725 E:1727 ||| NN
< ||| S:1727 E:1729 ||| SYM
0.05 ||| S:1729 E:1733 ||| CD
) ||| S:1733 E:1734 ||| -RRB-
;  ||| S:1734 E:1736 ||| :
( ||| S:1736 E:1737 ||| -LRB-
3 ||| S:1737 E:1738 ||| LS
)  ||| S:1738 E:1740 ||| -RRB-
correlation  ||| S:1740 E:1752 ||| JJ
analysis  ||| S:1752 E:1761 ||| NN
showed  ||| S:1761 E:1768 ||| VBD
that  ||| S:1768 E:1773 ||| DT
serum  ||| S:1773 E:1779 ||| JJ
folate  ||| S:1779 E:1786 ||| JJ
level  ||| S:1786 E:1792 ||| NN
in  ||| S:1792 E:1795 ||| IN
schizophrenia  ||| S:1795 E:1809 ||| JJ
group  ||| S:1809 E:1815 ||| NN
had  ||| S:1815 E:1819 ||| VBD
a  ||| S:1819 E:1821 ||| DT
negative  ||| S:1821 E:1830 ||| JJ
correlation  ||| S:1830 E:1842 ||| NN
with  ||| S:1842 E:1847 ||| IN
HCY  ||| S:1847 E:1851 ||| NNP
level  ||| S:1851 E:1857 ||| NN
( ||| S:1857 E:1858 ||| -LRB-
r  ||| S:1858 E:1860 ||| LS
=  ||| S:1860 E:1862 ||| SYM
-0.418 ||| S:1862 E:1868 ||| CD
,  ||| S:1868 E:1870 ||| ,
P  ||| S:1870 E:1872 ||| NNP
< ||| S:1872 E:1874 ||| SYM
0.001 ||| S:1874 E:1879 ||| NNP
)  ||| S:1879 E:1881 ||| -RRB-
.  ||| S:1881 E:1883 ||| .
Serum  ||| S:1883 E:1889 ||| NNP
HCY  ||| S:1889 E:1893 ||| NNP
level  ||| S:1893 E:1899 ||| NN
had  ||| S:1899 E:1903 ||| VBD
a  ||| S:1903 E:1905 ||| DT
positive  ||| S:1905 E:1914 ||| JJ
correlation  ||| S:1914 E:1926 ||| NN
with  ||| S:1926 E:1931 ||| IN
negative  ||| S:1931 E:1940 ||| JJ
symptoms  ||| S:1940 E:1949 ||| NNS
scores  ||| S:1949 E:1956 ||| NNS
( ||| S:1956 E:1957 ||| -LRB-
r  ||| S:1957 E:1959 ||| LS
=  ||| S:1959 E:1961 ||| SYM
0.345 ||| S:1961 E:1966 ||| CD
,  ||| S:1966 E:1968 ||| ,
P  ||| S:1968 E:1970 ||| NNP
< ||| S:1970 E:1972 ||| SYM
0.001 ||| S:1972 E:1977 ||| NNP
)  ||| S:1977 E:1979 ||| -RRB-
and  ||| S:1979 E:1983 ||| CC
serum  ||| S:1983 E:1989 ||| JJ
folate  ||| S:1989 E:1996 ||| JJ
level  ||| S:1996 E:2002 ||| NN
was  ||| S:2002 E:2006 ||| VBD
negatively  ||| S:2006 E:2017 ||| RB
correlated  ||| S:2017 E:2028 ||| VBN
with  ||| S:2028 E:2033 ||| IN
negative  ||| S:2033 E:2042 ||| JJ
symptoms  ||| S:2042 E:2051 ||| NNS
scores  ||| S:2051 E:2058 ||| NNS
( ||| S:2058 E:2059 ||| -LRB-
r  ||| S:2059 E:2061 ||| LS
=  ||| S:2061 E:2063 ||| SYM
-0.386 ||| S:2063 E:2069 ||| CD
,  ||| S:2069 E:2071 ||| ,
P  ||| S:2071 E:2073 ||| NNP
< ||| S:2073 E:2075 ||| SYM
0.001 ||| S:2075 E:2080 ||| NNP
) ||| S:2080 E:2081 ||| -RRB-
;  ||| S:2081 E:2083 ||| :
( ||| S:2083 E:2084 ||| -LRB-
4 ||| S:2084 E:2085 ||| LS
)  ||| S:2085 E:2087 ||| -RRB-
the  ||| S:2087 E:2091 ||| DT
serum  ||| S:2091 E:2097 ||| JJ
HCY  ||| S:2097 E:2101 ||| NNP
level  ||| S:2101 E:2107 ||| NN
in  ||| S:2107 E:2110 ||| IN
schizophrenia  ||| S:2110 E:2124 ||| JJ
group  ||| S:2124 E:2130 ||| NN
with  ||| S:2130 E:2135 ||| IN
TT  ||| S:2135 E:2138 ||| NNP
genotype  ||| S:2138 E:2147 ||| NN
was  ||| S:2147 E:2151 ||| VBD
significantly  ||| S:2151 E:2165 ||| RB
higher  ||| S:2165 E:2172 ||| JJR
than  ||| S:2172 E:2177 ||| IN
those  ||| S:2177 E:2183 ||| DT
with  ||| S:2183 E:2188 ||| IN
CC  ||| S:2188 E:2191 ||| NNP
and  ||| S:2191 E:2195 ||| CC
CT  ||| S:2195 E:2198 ||| NNP
genotypes  ||| S:2198 E:2208 ||| NNS
( ||| S:2208 E:2209 ||| -LRB-
P  ||| S:2209 E:2211 ||| NNP
< ||| S:2211 E:2213 ||| SYM
0.05 ||| S:2213 E:2217 ||| CD
) ||| S:2217 E:2218 ||| -RRB-
.  ||| S:2218 E:2220 ||| .
There  ||| S:2220 E:2226 ||| EX
is  ||| S:2226 E:2229 ||| VBZ
a  ||| S:2229 E:2231 ||| DT
certain  ||| S:2231 E:2239 ||| JJ
correlation  ||| S:2239 E:2251 ||| NN
between  ||| S:2251 E:2259 ||| IN
the  ||| S:2259 E:2263 ||| DT
serum  ||| S:2263 E:2269 ||| JJ
levels  ||| S:2269 E:2276 ||| NNS
of  ||| S:2276 E:2279 ||| IN
folate  ||| S:2279 E:2286 ||| NN
and  ||| S:2286 E:2290 ||| CC
HCY  ||| S:2290 E:2294 ||| NNP
and  ||| S:2294 E:2298 ||| CC
the  ||| S:2298 E:2302 ||| DT
symptoms  ||| S:2302 E:2311 ||| NNS
of  ||| S:2311 E:2314 ||| IN
schizophrenia ||| S:2314 E:2327 ||| NN
.  ||| S:2327 E:2329 ||| .
And  ||| S:2329 E:2333 ||| CC
MTHFR  ||| S:2333 E:2339 ||| NNP
C677T  ||| S:2339 E:2345 ||| NNP
polymorphism  ||| S:2345 E:2358 ||| NN
is  ||| S:2358 E:2361 ||| VBZ
a  ||| S:2361 E:2363 ||| DT
possible  ||| S:2363 E:2372 ||| JJ
risk  ||| S:2372 E:2377 ||| NN
factor  ||| S:2377 E:2384 ||| NN
for  ||| S:2384 E:2388 ||| IN
schizophrenia ||| S:2388 E:2401 ||| NN
.  ||| S:2401 E:2403 ||| .
